Acorda Therapeutics President and CEO Ron Cohen Receives New York Biotechnology Association Business Leader of the Year Award

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.D., President and Chief Executive Officer, is the recipient of the New York Biotechnology Association (NYBA) "The Cures Start Here” Business Leader of the Year Award. The award is presented for outstanding service to the patient community and to NYBA.

"Under Dr. Cohen’s leadership, Acorda recently received FDA approval for AMPYRA™, which represents a significant contribution to the treatment of people with multiple sclerosis,” said Nathan Tinker, Ph.D., Executive Director of NYBA. "Acorda exemplifies the vibrancy of the New York biotechnology industry and NYBA is pleased to recognize Dr. Cohen for his dedication to helping people with neurological disease, and for his ongoing commitment to the growth of the biotechnology industry in New York.”

Acorda Therapeutics, Inc. has been based on Hawthorne, NY since 1998. A native New Yorker, Dr. Cohen founded Acorda in 1995 as a private company dedicated to developing novel medications for people with neurological diseases. Today, Acorda is a publicly traded company with two marketed products, including AMPYRA™ (dalfampridine) Extended Release Tablets, 10 mg, which was recently approved by the U.S. Food and Drug Administration.

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company developing therapies for multiple sclerosis, spinal cord injury and other nervous system disorders. The Company's marketed products include AMPYRA™ (dalfampridine) Extended Release Tablets, 10 mg, a potassium channel blocker approved as a treatment to improve walking in patients with multiple sclerosis (MS); this was demonstrated by an improvement in walking speed; and ZANAFLEX CAPSULES^® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Because of the short duration of effect, treatment with ZANAFLEX CAPSULES should be reserved for those daily activities and times when relief of spasticity is most important. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Ampyra in the United States and to successfully market Zanaflex Capsules, the risk of unfavorable results from future studies of Ampyra, the occurrence of adverse safety events with our products, delays in obtaining or failure to obtain regulatory approval of Ampyra outside of the United States and our dependence on our collaboration partner Biogen Idec in connection therewith, competition, failure to protect Acorda Therapeutics’ intellectual property or to defend against the intellectual property claims of others, the ability to obtain additional financing to support Acorda Therapeutics' operations, and unfavorable results from our preclinical programs. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.